Evidence map›Paper›PMID 36642242›Full record

ArticleJournal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus2023

Smartphone application links severity of retinopathy of prematurity to early motor behavior in a cohort of high-risk preterm infants.

Sarah Hilkert Rodriguez, Michael P Blair, Elise Timtim, Ryan Millman, Zhuangjun Si, Kristen Wroblewski, Bree Andrews, Michael E Msall, Colleen Peyton

Open access · greenAbstract read
In one paragraph

Article in Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Sarah Hilkert RodriguezDepartment of Ophthalmology and Visual Science, University of Chicago, Chicago, Illinois. Electronic address: srodriguez5@bsd.uchicago.edu.
Michael P BlairDepartment of Ophthalmology and Visual Science, University of Chicago, Chicago, Illinois; Retina Consults Ltd, Des Plaines, Illinois.
Elise TimtimDepartment of Ophthalmology and Visual Science, University of Chicago, Chicago, Illinois.
Ryan MillmanDepartment of Physical Therapy and Human Movement Science, Northwestern University.
Zhuangjun SiDepartment of Ophthalmology and Visual Science, University of Chicago, Chicago, Illinois.
Kristen WroblewskiDepartment of Public Health, University of Chicago, Chicago, Illinois.
Bree AndrewsDepartment of Pediatrics, Section of Neonatology, University of Chicago.
Michael E MsallDepartment of Pediatrics, Section of Developmental and Behavioral Pediatrics and Kennedy Research Center on Neurodevelopmental Disabilities, University of Chicago, Chicago, Illinois.
Colleen PeytonDepartment of Physical Therapy and Human Movement Science, Northwestern University.
University of Chicago · USNorthwestern University · USChicago Department of Public Health · US

Funding

Northwestern University Clinical and Translational Science Institute (NUCATS)KL2TR001424 · NCATS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI SHARMA, LEENA · 2015 to 2023
$8.1M
NCATS NIH HHS KL2 TR001424
6 · The paper itself

Abstract

purposeTo evaluate the General Movement Assessment (GMA) with the Motor Optimality Score-Revised (MOS-R) as a neurodevelopmental marker in infants with retinopathy of prematurity (ROP).

methodsInfants screened prospectively for ROP were evaluated at 3 months' post-term age using a smartphone application to complete the GMA and MOS-R. Results were analyzed by ROP severity.

resultsOf 105 enrolled infants, 83 completed the study. Of these, 54 (65%) had any ROP, 32 (39%) had severe ROP, and 13 (16%) had type 1 ROP. The proportion with aberrant GMA was significantly higher in infants with severe ROP (14/32 [44%]) compared with infants who had milder ROP (8/51 [16%]; P = 0.006). Of those with severe ROP, there was no significant difference comparing infants with type 1 ROP treated with bevacizumab (7/13 [54%]) to infants with type 2 ROP without treatment (7/19 [37%]; P = 0.47). Although the presence of any ROP, stage of ROP, and severe ROP each predicted lower MOS-R scores on univariate analyses, only severe bronchopulmonary dysplasia and markers of brain injury remained significant in the multivariate analysis.

conclusionsThe GMA was a convenient, short-term method of data collection with low attrition. Although severe ROP initially appeared linked to poor early motor scores, this association is likely confounded by neurological and respiratory complications, which frequently accompany severe ROP.

Indexed as

Bronchopulmonary DysplasiaRetinopathy of PrematurityBevacizumabGestational AgeHumansInfantInfant, NewbornInfant, PrematureRetrospective StudiesSmartphoneBevacizumab

Identifiers

PMID36642242
PMCPMC10243477
OpenAlexW4316039493

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.